NewYork-Presbyterian/Columbia, a Kidney Precision Medicine Project recruitment site, is working to understand the cell types that are specific to kidney injury and can be targeted with new therapeutic agents.

Clinicians and researchers brought the important issue of caregiver burden to the fore and are seeking ways to not only identify and assess caregivers’ needs, but also to provide interventions to support them.

A physician-scientist at NewYork-Presbyterian/Columbia has set her sights on applying the discoveries made in her lab to improve tissue healing and treatment for the many diseases that can affect the gut.

The DiLumen Endolumenal Interventional Platform (EIP) developed at NewYork-Presbyterian/Weill Cornell is paving the way for dramatic changes in the treatment of many intestinal diseases.

While the use of fecal material as a medical remedy dates back to the fourth century, usage waned. In recent years, fecal microbiota transplant to control multiple relapses of Clostridium difficile infections is rising.

The Pancreatic Cyst Surveillance Program at NewYork-Presbyterian/Columbia helps identify patients with pancreatic cysts who are at risk for developing cancer and those who are not.

Dr. Goncalves has developed a mouse model that recapitulates the cachexia syndrome as they seek interventions – either dietary or metabolic – to help prevent muscle wasting and fat loss.

We found that insulin production decreases long before a patient is actually diagnosed with type 1 diabetes. Now that we know that a reduction in insulin production begins earlier on, we can diagnose T1D earlier in patients with antibody screening.